Ebola vaccine gives 100% protection, trial shows

The trial used a “ring vaccination” approach.

Although the side effects are bearable in the midst of an outbreak, these may discourage the general population from getting vaccinated when there is no looming threat of an Ebola infection. There was no cure.

The Ebola virus was first identified in 1976 and caused sporadic outbreaks in Africa. Almost 30,000 were infected.

According to the World Health Organization, three of the five subtypes have been associated with large hemorrhagic fever outbreaks; Ebola-Zaire, Ebola-Sudan and Ebola-Bundibugyo.

The final results of a certain clinical trial have recently suggested that the vaccine for Ebola has just been discovered.

The positive results led the study organizers to provide the vaccine to all people who had come in contact with Ebola patients.

The vaccine, however, is not flawless.

Now, no vaccine – or drug for that matter – is flawless.

USA and European regulatory agencies are now fast-tracking an Ebola vaccine found to be 100 percent effective during human trials.

The vaccine was tested first in several animal species, including mice, hamsters, guinea pigs and nonhuman primates. So it will likely decrease as the vaccine is used over time.

Her team of three dozen researchers calculated a 90 percent likelihood during a full-fledged epidemic that the vaccine, dubbed rVSV-ZEBOV, would work in more than 80 percent of cases.

The outbreak provided the sociopolitical and economic incentive for research into an effective Ebola vaccine – efforts that, over the past four decades, had failed to bear fruit.

Ebola, believed to originate in fruit bats, is an often-fatal disease transmitted through contact with infected animals or with bodily fluids of infected people.

This is especially promising because people chosen for the trial were friends, family and associates of an individual who contracted ebola during the height of the outbreak in 2015. A handful of cases were also found in Europe and the United States. No one got sick. Towards the end of the outbreak, Merck was ready to run a large-scale trial to test the effectiveness of its experimental vaccine rVSV-ZEBOV. That’s predicted to happen sometime in 2018.

“That is a good one for humanity”.

“For example, we don’t know how durable the vaccine is”, he said.

The Food and Drug Administration gave the vaccine breakthrough designation to allow quick licensing. “That’s very important to learn”. Approximately half of these social circles were offered vaccine.

Dr. Seth F. Berkley, chief executive of Gavi, the Vaccine Alliance, said his organization’s board voted in late 2014 to spend up to $390 million for 12 million doses of an Ebola vaccine.